Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer
- PMID: 35135135
- DOI: 10.1200/PO.18.00039
Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer
Similar articles
-
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.
-
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.Mol Cancer Ther. 2018 Feb;17(2):455-463. doi: 10.1158/1535-7163.MCT-17-0419. Epub 2017 Dec 13. Mol Cancer Ther. 2018. PMID: 29237803
-
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.Expert Rev Anticancer Ther. 2020 May;20(5):333-341. doi: 10.1080/14737140.2020.1747439. Epub 2020 Apr 8. Expert Rev Anticancer Ther. 2020. PMID: 32223357 Review.
-
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.Expert Opin Investig Drugs. 2015;24(11):1493-500. doi: 10.1517/13543784.2015.1096344. Epub 2015 Oct 12. Expert Opin Investig Drugs. 2015. PMID: 26457764 Review.
-
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.Ther Clin Risk Manag. 2018 Jul 20;14:1247-1252. doi: 10.2147/TCRM.S147381. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 30050303 Free PMC article. Review.
Cited by
-
Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.Cancer Lett. 2021 Jan 28;497:221-228. doi: 10.1016/j.canlet.2020.10.039. Epub 2020 Oct 28. Cancer Lett. 2021. PMID: 33127389 Free PMC article. Clinical Trial.
-
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Target Oncol. 2024 Sep;19(5):679-689. doi: 10.1007/s11523-024-01088-3. Epub 2024 Aug 10. Target Oncol. 2024. PMID: 39123077 Review.
-
Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations.JTO Clin Res Rep. 2020 Sep 18;2(2):100100. doi: 10.1016/j.jtocrr.2020.100100. eCollection 2021 Feb. JTO Clin Res Rep. 2020. PMID: 34589979 Free PMC article.
-
The road to overcome pancreatic cancer: Where are we?Heliyon. 2024 Sep 19;10(19):e38196. doi: 10.1016/j.heliyon.2024.e38196. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39403527 Free PMC article. Review.
-
Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine.Clin Colorectal Cancer. 2023 Mar;22(1):2-11. doi: 10.1016/j.clcc.2022.11.001. Epub 2022 Nov 4. Clin Colorectal Cancer. 2023. PMID: 36418197 Free PMC article. Review.
LinkOut - more resources
Full Text Sources